TVR5 retweeted
Hola from Barcelona 🇪🇸 and #ENA26 - our first #StartWithWhy episode. Everything we work on Starts with Why … our focus on the unmet need identified TopoI resistance as a key driver in the clinic. Combination therapy in one medicine saves years of development time. #AVCT
In today’s R&D Spotlight, the team give a preview of this week’s data with our first clinical candidate in the Dual Payload pre|CISION pipeline. We discuss our “Why” and the large unmet needs in solid tumors that this program is designed to address. avacta.wistia.com/s/d3q9sfy8… #AVCT
#AVCT’s AVA6207 has big ambitions.
Large indications targeted:
NSCLC: 100 -150k
CRC: 60-85k
Orphan indications targeted:
Ovarian: 14-21k
Esophageal: 4-16k
In today’s R&D Spotlight, the team give a preview of this week’s data with our first clinical candidate in the Dual Payload pre|CISION pipeline. We discuss our “Why” and the large unmet needs in solid tumors that this program is designed to address. avacta.wistia.com/s/d3q9sfy8… #AVCT
In today’s R&D Spotlight, the team give a preview of this week’s data with our first clinical candidate in the Dual Payload pre|CISION pipeline. We discuss our “Why” and the large unmet needs in solid tumors that this program is designed to address. avacta.wistia.com/s/d3q9sfy8… #AVCT
#AVCT
AVA6000 is doubling PFS in SGC. The drug is working in TNBC and STS. It works where Dox works, as designed.
AVA6103 is 33w into clinic, 6 indications, 2 arms, 7 sites. Replicating pre-clinical performance.
AVA6207 is released tomorrow.
3 Generations of drug. 1 platform.
TVR5 retweeted
Delighted to bring a fresh look at #AVCT ESMO presentations from our TMED team. Our pre|CISION platform data inform HOW the durable release occurs. This is a masterclass in the feedback loop of information in biotech. An observation in Ph 1 explained in preclinical models.
In this Episode of the R&D Spotlight Series, the team discuss the key findings from our ESMO data. One important finding is that tumors recruit fibroblasts during treatment, leading to an increased ability to release the payload.
avacta.wistia.com/s/59m12mns… #AVCT
#AVCT will reveal its Gen3 drug AVA6207 next week.
AVA6207 is, at its core, AVA6103 plus an additional docking site.
A working AVA6103 greatly increases the value of AVA6207.
The owner of the ATRi warhead has a direct interest in the AVA6103 biopsies which are now rolling in.
In this Episode of the R&D Spotlight Series, the team discuss the key findings from our ESMO data. One important finding is that tumors recruit fibroblasts during treatment, leading to an increased ability to release the payload.
avacta.wistia.com/s/59m12mns… #AVCT
#AVCT releases the warheads which will make up AVA6207 next week.
The foundation of AVA6207 is AVA6103. Now proven in human.
Ownership of the ATR inhibitor, which will sit alongside Exatecan in AVA6207, will be highly informative.
Who owns the green payload AVCT seeks to use?
“Always important to have the ‘safe bets’ as well as the moonshots that exist under the surface.”
AVA6103 7+ months into clinic at this point; through 5 cohorts; across 6 indications; and backfilling with mandatory biopsies.
October was always a very important month for #AVCT.
Great discussion today at the @LongwoodLeaders forum in Boston on prioritizing the pipeline. Delighted to discuss the #AVCT pipeline & how we make hard decisions: sure bets v. Moonshots and those between. Big pharma and biotech have similar priority: patient impact
#LetsDoThis
Our CEO Christina Coughlin participating in the Prioritizing the Pipeline panel with @LongwoodLeaders in Boston today, discussing how we assess our platform opportunities to deliver high patient impact. #AVCT lnkd.in/p/ePwyn4yx
CEO Christina Coughlin and CFO Brian Hahn will be at @Jefferies Healthcare Conference, Nov 16-19 in London. Curious how pre|CISION® keeps potent payloads silent in the bloodstream and active in the tumor? Book a 1:1 via the partnering system. avacta.com/avacta-participat… #AVCT














